• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Evolus Inc.

    6/16/25 4:03:36 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EOLS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001700836
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    EVOLUS, INC.
    SEC File Number
    001-38381
    Address of Issuer
    520 Newport Center Drive, Suite 1200
    Newport Beach
    CALIFORNIA
    92660
    Phone
    (949) 284-4555
    Name of Person for Whose Account the Securities are To Be Sold
    DAVID MOATAZEDI
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    16582164052.366447558906/16/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common05/09/2025Performance SharesIssuerCheckbox not checked1481405/09/2025Not Applicable
    Common03/26/2025Restricted StockIssuerCheckbox not checked176803/26/2025Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common06/13/2025419542172.75
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common06/13/202516135162206.77
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common06/13/2025989999515.64
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common06/13/202525617257530.26
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common06/13/202522465225842.89
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common06/13/202533012331872.94
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common05/12/202515787155754.54
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common03/27/2025625177512.40
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common03/18/20251037361375020.68

    144: Remarks and Signature

    Remarks
    Date of Notice
    06/16/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ David Moatazedi

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $EOLS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EOLS

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    BTIG Research
    1/29/2024$10.00 → $16.00Equal Weight → Overweight
    Barclays
    6/23/2022$18.00Buy
    Needham
    5/12/2022$8.00 → $10.00Underweight → Equal Weight
    Barclays
    1/20/2022$11.00Hold → Buy
    Truist
    11/3/2021$22.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EOLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Moatazedi David sold $1,283,195 worth of shares (127,905 units at $10.03), decreasing direct ownership by 26% to 364,927 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      6/16/25 4:42:06 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director White Albert G Iii bought $189,000 worth of shares (20,000 units at $9.45), increasing direct ownership by 66% to 50,378 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      6/10/25 5:04:47 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Avelar Rui sold $33,397 worth of shares (3,385 units at $9.87), decreasing direct ownership by 0.93% to 359,082 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      5/14/25 7:27:50 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in June of non-qualified stock options to purchase an aggregate of 11,628 shares of Evolus and an aggregate of 36,077 restricted stock units (RSUs) of the company's common stock to 17 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus 2023 Inducement Incentive Plan, with a grant date of June 8, 2025 and vesting commencement date of June 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accor

      6/13/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolysse™ Recognized in 2025 Shape Skin Awards

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, is proud to announce it has been recognized with two Shape 2025 Skin Awards: Evolysse™ Recognized as the Best Filler for 2025 with its recently launched injectable hyaluronic acid gel line Best Membership Treatment Model for Club Evolus™, its proprietary consumer rewards program The annual Shape Skin Awards highlight innovation and performance across the skincare and aesthetics industry. This year the judging panel of board-certified dermatologists and specialists evaluated more than 800 products and treatments, ultimately selecting winners across a range of

      6/10/25 8:00:00 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Announces Departure of its Chief Financial Officer

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has resigned effective June 13, 2025, to accept the same position at a private mental health and wellness technology company. Ms. Beaver's resignation is not a result of any disagreement related to the company's operations, policies or practices, including any accounting principles and practices, or related to any financial statements or disclosures. "On behalf of our employees, our leadership team, and our Board of Directors, I want to thank Sandra for her contributions to Evolus," said David Moatazed

      5/27/25 4:15:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director White Albert G Iii bought $189,000 worth of shares (20,000 units at $9.45), increasing direct ownership by 66% to 50,378 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      6/10/25 5:04:47 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    SEC Filings

    See more
    • SEC Form 144 filed by Evolus Inc.

      144 - Evolus, Inc. (0001570562) (Subject)

      6/16/25 4:03:36 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Evolus, Inc. (0001570562) (Filer)

      6/6/25 4:20:52 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Evolus, Inc. (0001570562) (Filer)

      5/27/25 4:18:36 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Leadership Updates

    Live Leadership Updates

    See more
    • Evolus Announces Appointment of Albert G. White III to Board of Directors

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

      7/1/24 8:00:00 AM ET
      $COO
      $EOLS
      Ophthalmic Goods
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program. Nareg will report to Sandra Beaver, Chief Financial Officer of Evolus. "I am thrilled to welcome Nareg to our team," said Sandra Beaver, Chief Financial Officer of Evolus. "Nareg's unique experience will enable him to drive a successful investor relati

      1/4/24 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

      Industry Leader Brings 20+ Years of Cosmetic Expertise to the Performance Beauty Category Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective today. Yamagishi-Dressler is an accomplished executive with more than two decades of established excellence leading omnichannel marketing for global beauty companies. A true strategist, Yamagishi-Dressler has successfully driven profitable business growth and increased equity for an iconic portfolio of industry brands. This press release features multimedia. View the full release here: https:

      8/21/23 8:45:00 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Evolus with a new price target

      BTIG Research initiated coverage of Evolus with a rating of Buy and set a new price target of $21.00

      4/17/25 8:32:06 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus upgraded by Barclays with a new price target

      Barclays upgraded Evolus from Equal Weight to Overweight and set a new price target of $16.00 from $10.00 previously

      1/29/24 7:09:38 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Evolus with a new price target

      Needham initiated coverage of Evolus with a rating of Buy and set a new price target of $18.00

      6/23/22 7:38:38 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care